razoxane has been researched along with Necrosis in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (12.50) | 18.7374 |
1990's | 2 (25.00) | 18.2507 |
2000's | 5 (62.50) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Schrijvers, DL | 1 |
Hasinoff, BB; Huebner, E; Marusak, RA; Patel, D; Schnabl, KL | 1 |
Buter, J; Dahlstrøm, K; de Wit, M; Eidtmann, H; Giaccone, G; Jensen, PB; Knoblauch, P; Langer, SW; Mouridsen, HT; Rasmussen, A; Rosti, G | 1 |
Schulmeister, L | 1 |
El-Hage, AN; Ferrans, VJ; Herman, EH | 1 |
Arstall, MA; Fukazawa, R; Kelly, RA; Sawyer, DB | 1 |
Ben-Yehuda, D; Lossos, IS | 1 |
Buter, J; Giaccone, G; Jensen, PB; Langer, SW; Sehested, M | 1 |
2 review(s) available for razoxane and Necrosis
Article | Year |
---|---|
Extravasation: a dreaded complication of chemotherapy.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Dimethyl Sulfoxide; Doxorubicin; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Injections, Intravenous; Mitomycin; Necrosis; Razoxane; Skin Ulcer | 2003 |
Totect: a new agent for treating anthracycline extravasation.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antidotes; Biopsy; Chelating Agents; Debridement; Drug Administration Schedule; Extravasation of Diagnostic and Therapeutic Materials; Humans; Necrosis; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Selection; Practice Guidelines as Topic; Razoxane; Skin Transplantation; Time Factors | 2007 |
1 trial(s) available for razoxane and Necrosis
Article | Year |
---|---|
Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibiotics, Antineoplastic; Debridement; DNA Topoisomerases, Type II; Enzyme Inhibitors; Europe; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Infusions, Intravenous; Length of Stay; Male; Middle Aged; Necrosis; Prospective Studies; Razoxane; Topoisomerase II Inhibitors; Treatment Outcome | 2007 |
5 other study(ies) available for razoxane and Necrosis
Article | Year |
---|---|
Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria.
Topics: Animals; Animals, Newborn; Apoptosis; Cardiovascular Agents; Cells, Cultured; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Heart Ventricles; Image Processing, Computer-Assisted; Indicators and Reagents; Intracellular Membranes; Membrane Potentials; Mitochondria, Heart; Myocytes, Cardiac; Necrosis; Rats; Rats, Sprague-Dawley; Razoxane; Reactive Oxygen Species | 2003 |
Examination of the protective effect of ICRF-187 and dimethyl sulfoxide against acetaminophen-induced hepatotoxicity in Syrian golden hamsters.
Topics: Acetaminophen; Alanine Transaminase; Animals; Blood Proteins; Chemical and Drug Induced Liver Injury; Cricetinae; Dimethyl Sulfoxide; Liver Diseases; Male; Mesocricetus; Necrosis; Piperazines; Razoxane | 1983 |
Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Cardiovascular Agents; Cells, Cultured; Daunorubicin; Dose-Response Relationship, Drug; Heart; Necrosis; Oxidative Stress; Rats; Rats, Sprague-Dawley; Razoxane; Superoxides | 1999 |
Cutaneous and subcutaneous necrosis following dexrazoxane-CHOP therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Cyclophosphamide; Doxorubicin; Fatal Outcome; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Necrosis; Prednisone; Razoxane; Skin; Vincristine | 1999 |
Dexrazoxane in anthracycline extravasation.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Extravasation of Diagnostic and Therapeutic Materials; Humans; Necrosis; Razoxane | 2000 |